Management of Stage I Nonseminomatous Germ Cell Tumors
- 1 August 2015
- journal article
- review article
- Published by Elsevier in Urologic Clinics of North America
- Vol. 42 (3) , 299-310
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active SurveillanceJournal of Clinical Oncology, 2015
- Primum non nocere: do we harm stage I testicular cancer patients less by applying adjuvant chemotherapy than by failing to present this option?Annals of Oncology, 2014
- Optimal Management of Clinical Stage I Testis Cancer: One Size Does Not Fit AllJournal of Clinical Oncology, 2013
- Active Surveillance Is the Preferred Approach to Clinical Stage I Testicular CancerJournal of Clinical Oncology, 2013
- Management of Low-stage Nonseminomatous Germ Cell Tumors of Testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009Urology, 2011
- [18F]-FDG–PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trialAnnals of Oncology, 2008
- Increasing Incidence of Testicular Germ Cell Tumors Among Black Men in the United StatesJournal of Clinical Oncology, 2005
- Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer: Impact of Patient Selection Factors on OutcomeJournal of Clinical Oncology, 2005
- CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria.American Journal of Roentgenology, 1997
- MIB-1 immunohistochemistry in clinical Stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasisCancer, 1997